title: Pharmacology and pharmacogenomics of neurological medications used in pregnancy.
abstract: Pregnancy increases the pharmacological management challenge of numerous neurological diseases as a result of complex physiological changes. Understanding pregnancy-induced changes in pharmacokinetic and pharmacodynamic parameters can lead to better outcomes for both the mother and baby. Although the application of pharmacogenomics in maternal-fetal medicine is in its infancy, further research and developments will provide important new developments for managing the efficacy of drug treatments during pregnancy and improving maternal-fetal safety. Although a wide variety of neurological medications are used during pregnancy, this article will focus on the drugs with currently known pharmacogenomic implications.
authors.affiliation: Department of Pediatrics, Division of Clinical Pharmacology, Clinical Trials Office, University of Utah, Salt Lake City, Utah, USA.
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Campbell
authors.forename: Michael G
authors.initials: MG
authors.lastname: Spigarelli
mesh_terms: D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D003061:Codeine / Q000494:pharmacology* / Q000627:therapeutic use; D003915:Dextromethorphan / Q000494:pharmacology; D005260:Female; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy*; D010597:Pharmacogenetics; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D013723:Teratogens / Q000494:pharmacology; D013747:Tetrabenazine / Q000494:pharmacology
chemical_list: D000927:Anticonvulsants; D013723:Teratogens; D003915:Dextromethorphan; D003061:Codeine; D013747:Tetrabenazine